-- Collaboration on developing & commercializing cardiovascular drugs --

On June 15th 2007, In Chul Kim CEO of LGLS representing LG Life Sciences and Ulf Nehrbass CEO of Institut Pasteur Korea met and had a ceremony for the agreement for collaboration research on cardiovascular diseases for developing drug candidates and commercializing drugs at LG Twin Tower.

The message of this agreement is indicating cooperation of two technologies? the visual screening technology by Institut Pastur Korea and the optimization, validation, and commercialization of drugs known by LGLS. LG-IPK Drug Development Center is planned to be established within two years. Financials terms and conditions were not disclosed.

In Chul Kim (CEO of LGLS) stated that the meaning of this collaboration can be expressed as “the basic research competence of IPK meets drug development capacity of LGLS which will create the synergy effect for the rapide cardiovascular drug development.”

“We are very exited to team up our visual screening competence with the outstanding drug development platform of LGLS” said IPK’s CEO Ulf Nehrbass